The impact of chemotherapy-induced peripheral neuropathy on sensory function of the hands: a mixed methods study (Jerosch-HeroldU17SF)
Chemotherapy-induced peripheral neuropathy (CIPN) is a significant side-effect of chemotherapy, which first causes pain, sensitivity and numbness in the hands and feet and then spreads proximally. It can result in a substantial reduction in quality of life and limitation of doses and number of cycles of chemotherapy treatment. It is estimated that 1/3rd of cancer survivors suffer some form of CIPN, some for a prolonged period of time. CIPN is recognised as an area of unmet need and given the increasing number of people who are diagnosed and survive cancer, CIPN places a significant long-term burden on the individual and society. No effective treatment is currently available which prevents or effectively treats CIPN.
This three-year mixed methods project will provided an opportunity to explore the impact of CIPN affecting the hands on everyday functioning and quality of life and begin to quantify the extent of pain and sensory disturbances affecting the hand. Study findings may inform future practice on how CIPN affecting the hands can be assessed and the development of interventions to manage CIPN.
The project activities may include a review of current literature on the impact of CIPN and methods of assessing CIPN in the hand, proposal development and ethics application, primary collection and analysis of qualitative and quantitative data on the impact of CIPN on hand function and quality of life, dissemination of project findings through conference presentations and publications.
Dr Christina Jerosch-Herold and Dr Gabby Thorpe will co-supervise this project bringing together a strong clinical and research track record in upper extremity sensory disorders and cancer care as well as expertise in quantitative and qualitative methods, respectively.
For more information on the supervisor for this project, please go here: https://www.uea.ac.uk/health-sciences/people/profile/c-jerosch-herold
Type of programme: PhD.
Start date of project: Flexible, from January 2018.
Mode of study: Full time.
The standard minimum entry requirement is 2:1 or above.
This PhD project is offered on a self-funding basis. It is open to applicants with funding or those applying to funding sources. Details of tuition fees can be found at http://www.uea.ac.uk/study/postgraduate/research-degrees/fees-and-funding.
A bench fee may also payable on top of the tuition fee to cover specialist equipment or laboratory costs required for the research. The amount charged annually will vary considerably depending on the nature of the project and applicants should contact the primary supervisor for further information about the fee associated with the project.
i) Cavaletti (2014) Chemotherapy-induced peripheral neurotoxicity (CIPN): what we need and what we know, J Periph Nerv Syst 19:66-76.